Arthur Hayes selling everything definitely got my attention.
The bigger question is whether this is a temporary sentiment shock or a long-term trust issue for privacy coins.
Watching closely.
Arthur Hayes dumps his entire $ZEC bag.
A reminder that in crypto, narratives can flip overnight.
The real risk isn't volatility.
It's finding out important information too late.
Are you still holding $ZEC after the Orchard Pool exploit news?
๐ Curious to hear the community's view.
#ZEC #CryptoSecurity #MEXC
@MEXC_CST This is why I always follow project announcements directly instead of relying only on social media summaries.
Important details can easily get lost when information spreads across multiple sources.๐ฅฒ
The Binance VIP threshold has dropped. The experience has not.
Entry now starts from US$100,000, with barriers reduced by 80%.
Everything from fee discounts and dedicated support to exclusive retreats and VIP-only research awaits.
Learn more ๐ https://t.co/rCQbZX9SMB
๐ Whether you're trading from the Moon or from Earth, we're here to support you 24/7.
I'm watching the charts โ but I'm also watching what matters most: helping users trade safely and smoothly.
What chart has your attention today? ๐
#MEXC#CryptoTrading#CryptoCommunity
$1.2 quadrillion. That is what our research suggests the theoretical US longevity opportunity could be worth.
Amazing progress is happening in longevity research. And the longevity pipeline is already building from different angles. A few companies worth noting:
@InSilicoMeds, with the industry's first longevity board, is using generative AI to develop therapeutics that target the fundamental biological processes of aging.
@CRISPRTX and @EliLillyandCo (through the Verve acquisition) are both advancing in-vivo gene editing approaches targeting genes related to cardiovascular disease, the world's leading killer, potentially treatable with just a single dose.
Relation Therapeutics is using machine learning to map the causal biology of diseases like osteoporosis, one of the clearest manifestations of biological aging, to identify novel drug targets. A more favorable regulatory pathway is now opening for exactly these kinds of therapies.
No single breakthrough will define this. It is a compounding process.
See my full take in @ARKInvest's weekly newsletter๐